Tesamorelin
FDA-approved GHRH analog for visceral fat reduction
Overview
Tesamorelin is an FDA-approved GHRH analog specifically indicated for reducing excess abdominal fat in HIV-associated lipodystrophy. It is one of the few FDA-approved peptide therapies for body composition.
Mechanism of Action
Synthetic GHRH analog → binds pituitary GHRH receptors → stimulates endogenous GH secretion → specifically targets visceral adipose tissue reduction → increases IGF-1.
Benefits
- FDA-approved
- Targeted visceral fat reduction
- Improved body composition
- Reduced triglycerides
- Cognitive benefits in aging
Dosing Protocol
Half-Life
~26–38 minutes
Duration of pharmacological activity after administration.
Side Effects
- Injection site reactions
- Joint pain
- Peripheral edema
- Myalgia
- Paresthesia
Stacking Recommendations
Storage & Reconstitution
Lyophilized: room temperature. Reconstituted: 2–8°C, use within 24 hours.
Research Notes
FDA-approved as Egrifta for HIV lipodystrophy. Studies show significant visceral fat reduction (~18%) and cognitive improvement in older adults. One of the most well-validated GH peptides.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.